Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1-Reference-Cited by-同舟云学术

Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1

Published:2022 Issue:9 Volume:3 Page:1111-1120
ISSN:2633-0679
Container-title:RSC Chemical Biology
language:en
Short-container-title:RSC Chem. Biol.

Author:

Tsuji Kohei¹²^ORCID,Hymel David¹,Ma Buyong³^ORCID,Tamamura Hirokazu²^ORCID,Nussinov Ruth³^ORCID,Burke Terrence R.¹^ORCID

Affiliation:

1. Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA

2. Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101-0062, Japan

3. Computational Structural Biology Section, Laboratory of Immunometabolism, Frederick National Laboratory for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA

Abstract

The polo-like kinase 1 (Plk1) is an important mediator of cell cycle regulation and a recognized anti-cancer molecular target.

Funder

National Cancer Institute

Japan Society for the Promotion of Science

Publisher

Royal Society of Chemistry (RSC)

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry,Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CB/D2CB00153E

Reference34 articles.

1. Multivalent ligand: design principle for targeted therapeutic delivery approach

2. Bivalent inhibitors of protein kinases

3. T.Pawson and P.Nash , in Handbook of Cell Signaling , ed. R. A. Bradshaw and E. A. Dennis , Academic Press , San Diego , 2nd edn, 2010 , pp. 399–411 10.1016/B978-0-12-374145-5.00057-7

4. Signaling—2000 and Beyond

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. Application of a Fluorescence Recovery-Based Polo-Like Kinase 1 Binding Assay to Polo-Like Kinase 2 and Polo-Like Kinase 3;Biological and Pharmaceutical Bulletin;2024-07-11

3. Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance;Annual Review of Pharmacology and Toxicology;2024-01-23

4. Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component;RSC Chemical Biology;2024

5. Leveraging the Fragment Molecular Orbital Method to Explore the PLK1 Kinase Binding Site and Polo-Box Domain for Potent Small-Molecule Drug Design;International Journal of Molecular Sciences;2023-10-27